Hyperuricemia and gout |
| |
Authors: | Frédéric Lioté |
| |
Institution: | 1.Centre Viggo Petersen,INSERUM U349 H?pital Lariboisière,Paris,France |
| |
Abstract: | Gout is not a new disease for clinicians; nevertheless, there are still many secrets awaiting discovery for improving knowledge
with respect to uric acid metabolism and monosodium urate crystal-induced inflammation. This review of the literature will
focus on new insights on the pathogenesis of idiopathic hyperuricemia, and on secondary hyperuricemia and gout. There are
also important advances on the pathophysiology of acute gout, especially as a self-limited process (switch from monocyte to
macrophage, peroxisome proliferator activated receptor-gamma, and nitric oxide), but also of chronic gouty arthropathy. Armaments
for treating hyperuricemia and gout may be already improved by losartan or fenofibrate and, in the future, by urate oxydase-polyethylene
glycol 20 and renal handling regulatory molecules. Finally, control of hyperuricemia may also be considered in the prevention
and treatment of cardiovascular disease. |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|